ACHIEVE -Aldosterone bloCkade for Health Improvement EValuation in End-stage renal disease
Details
a) Background:
A randomized placebo controlled trial to assess the safety and efficacy of spironolactone on cardiovascular outcomes among patients with end-stage renal disease
b) Objectives:
Primary: To determine if spironolactone reduces cardiac morbidity and mortality for patients treated with chronic dialysis.
Secondary: To assess the safety and other efficacy of spironolactone in patients treated with chronic dialysis